These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 22508869)

  • 1. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials.
    Garcia-Doval I; Carretero G; Vanaclocha F; Ferrandiz C; Daudén E; Sánchez-Carazo JL; Alsina M; Herrera-Ceballos E; Gómez-García FJ; Ferrán M; López-Estebaranz JL; Hernanz JM; Belinchón-Romero I; Vilar-Alejo J; Rivera R; Carrascosa JM; Carazo C
    Arch Dermatol; 2012 Apr; 148(4):463-70. PubMed ID: 22508869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry.
    Carretero G; Ferrandiz C; Dauden E; Vanaclocha Sebastián F; Gómez-García FJ; Herrera-Ceballos E; De la Cueva-Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina-Gibert M; López-Estebaranz JL; Ferrán M; Torrado R; Carrascosa JM; Carazo C; Rivera R; Jiménez-Puya R; García-Doval I;
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):156-63. PubMed ID: 24684267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry.
    Medina C; Carretero G; Ferrandiz C; Dauden E; Vanaclocha F; Gómez-García FJ; Herrera-Ceballos E; De la Cueva-Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina M; López-Estebaranz JL; Ferrán M; Carrascosa JM; Torrado R; Argila D; Rivera R; Jiménez-Puya R; García-Doval I;
    J Eur Acad Dermatol Venereol; 2015 May; 29(5):858-64. PubMed ID: 25185962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of treatment with biologics for psoriasis in daily practice: 5-year data.
    van Lümig PP; Driessen RJ; Berends MA; Boezeman JB; van de Kerkhof PC; de Jong EM
    J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):283-91. PubMed ID: 21435026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Kalb RE; Fiorentino DF; Lebwohl MG; Toole J; Poulin Y; Cohen AD; Goyal K; Fakharzadeh S; Calabro S; Chevrier M; Langholff W; You Y; Leonardi CL
    JAMA Dermatol; 2015 Sep; 151(9):961-9. PubMed ID: 25970800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations.
    Menter A; Reich K; Gottlieb AB; Bala M; Li S; Hsu MC; Guzzo C; Diels J; Gelfand JM
    J Drugs Dermatol; 2008 Dec; 7(12):1137-46. PubMed ID: 19137767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.
    Gottlieb AB; Kalb RE; Langley RG; Krueger GG; de Jong EM; Guenther L; Goyal K; Fakharzadeh S; Chevrier M; Calabro S; Langholff W; Menter A
    J Drugs Dermatol; 2014 Dec; 13(12):1441-8. PubMed ID: 25607786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry.
    Inzinger M; Heschl B; Weger W; Hofer A; Legat FJ; Gruber-Wackernagel A; Tilz H; Salmhofer W; Quehenberger F; Wolf P
    Br J Dermatol; 2011 Sep; 165(3):640-5. PubMed ID: 21564068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population.
    Asgari MM; Ray GT; Geier JL; Quesenberry CP
    J Am Acad Dermatol; 2017 Apr; 76(4):632-638. PubMed ID: 28162854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data.
    Rustin MH
    Br J Dermatol; 2012 Nov; 167 Suppl 3():3-11. PubMed ID: 23082810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization.
    Hordijk-Trion M; Lenzen M; Wijns W; de Jaegere P; Simoons ML; Scholte op Reimer WJ; Bertrand ME; Mercado N; Boersma E;
    Eur Heart J; 2006 Mar; 27(6):671-8. PubMed ID: 16423872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis.
    Yiu ZZN; Mason KJ; Barker JNWN; Hampton PJ; McElhone K; Smith CH; Warren RB; Griffiths CEM; Lunt M; Burden AD;
    Br J Dermatol; 2019 Dec; 181(6):1265-1271. PubMed ID: 30822358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study.
    Abuabara K; Lee H; Kimball AB
    Br J Dermatol; 2011 Nov; 165(5):1066-73. PubMed ID: 21777216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serious infections among a large cohort of subjects with systemically treated psoriasis.
    Dobry AS; Quesenberry CP; Ray GT; Geier JL; Asgari MM
    J Am Acad Dermatol; 2017 Nov; 77(5):838-844. PubMed ID: 28917384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan.
    Chen YJ; Wu CY; Chen TJ; Shen JL; Chu SY; Wang CB; Chang YT
    J Am Acad Dermatol; 2011 Jul; 65(1):84-91. PubMed ID: 21458106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of biologic agents in pediatric psoriasis.
    Marji JS; Marcus R; Moennich J; Mackay-Wiggan J
    J Drugs Dermatol; 2010 Aug; 9(8):975-86. PubMed ID: 20684148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: a nationwide cohort study.
    Chen YJ; Chang YT; Shen JL; Chen TT; Wang CB; Chen CM; Wu CY
    Arthritis Rheum; 2012 Jun; 64(6):1879-87. PubMed ID: 22161801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. External validity of clinical trials in acute myocardial infarction.
    Steg PG; López-Sendón J; Lopez de Sa E; Goodman SG; Gore JM; Anderson FA; Himbert D; Allegrone J; Van de Werf F;
    Arch Intern Med; 2007 Jan; 167(1):68-73. PubMed ID: 17210880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential outcomes after sirolimus-eluting stent implantation: comparing on-label versus off-label patients in the 'real world'.
    Jeremias A; Ruisi CP; Kirtane AJ; Lee T; Sylvia B; Pinto DS; Ho KK; Cutlip DE; Carrozza JP; Cohen DJ
    Coron Artery Dis; 2008 Mar; 19(2):111-5. PubMed ID: 18300748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study.
    Stern RS;
    J Am Acad Dermatol; 2012 Apr; 66(4):553-62. PubMed ID: 22264671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.